March 1, 2015 Reading the Yee-Leaves: Biotech sentiment, top questions, ideas
Top discussions: 1) BIIB: Expectations and sentiment around BIIB-037 Alzheimer's data at AD/PD March 20th, Are LINGO expectations now actually even lower post AON data and hence better set up? 2) CELG: Does May 7th EU patent decision matter and how much? Will generalists buy the dip if stock overreacts since impact is minor and not USA read-through? 3) VRTX: What does '661 data need to show to satisfy investors and are expectations low enough now for March data? Will Street realize they can do $10 earnings power or this is too far out to matter? 4) GILD: What do Q1 Hep C scripts imply now and does this suggest a beat and will company be aggressively buying stock in H1? Will GILD buy something meaningful this year and what could it be? 5) ICPT: what will GenFit show and are people waiting for this before stepping in? 6) DYAX: What is good data for DX-2930 in April? 7) UTHR: Is company getting closer to selling itself with transition of CEO and departure of CFO now? 8) PCYC: walking through valuation methods and rationale for acquisition scenarios by JNJ or others (standstill far out but voided if 3rd party makes offer). O